Archives for July, 2018
WuXi’s API production site in china passes USFDA’s inspection
Custom Synthesis, WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from the Food...
Neurodegeneration may be tied to drainage issues in the brain
Custom Synthesis, PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system, based on the...
Positive data supports product opportunities for XF-73 in dermal infection indications
Custom Synthesis, Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s lead candidate for...
UKCloud Health joins the Global Alliance for Genomics and Health
Custom Synthesis, UKCloud Health, the easy to adopt, use, and leave assured cloud services company, today announced that it has become a member of the...
Tradjenta’s Carmelina cardiovascular outcome trial meets primary endpoint
Custom Synthesis, Boehringer Ingelheim and Eli Lilly released the positive top-line results from the trial, which evaluated the impact of treatment with Tradjenta compared with...
Better prevention can curbe significant disruption to daily life and work caused by migraine
Custom Synthesis, Novartis and the European Migraine and Headache Alliance (EMHA) Wednesday presented initial findings from the largest global migraine patient study to date, involving...
Sanofi and Advent in negotiations for €1.9 billion acquisition of Zentiva
Custom Synthesis, Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the companies have signed...
Novartis aims at spinoff of Alcon eye care devices business
Custom Synthesis, Novartis on Friday said it intends to spinoff Alcon, its eye care division, into a separately-traded standalone company, which would enable Novartis and...
CHMP recommends approval of Sanofi’s Cablivi
Custom Synthesis, The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe for the treatment...
AstraZeneca’s lung cancer drug approved in Japan
Custom Synthesis, AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi...